2018
DOI: 10.1016/j.urology.2017.10.032
|View full text |Cite
|
Sign up to set email alerts
|

Bladder Herpes Infection in a Patient With Low-grade Non–Muscle-invasive Bladder Cancer

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2021
2021
2021
2021

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 3 publications
0
1
0
Order By: Relevance
“…The antitumor effect of SFN was associated with downregulation of both the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor 2 (HER2/neu) [ 106 ]. This is remarkable, since inhibition of either EGFR or HER2 signaling has been shown to correlate with enhanced p38 MAPK phosphorylation [ 134 ]. Gemcitabine or cisplatin treatment in human bladder cancer models has been shown to cause a dose-dependent release of ROS and activate the p38 MAPK-signaling pathway [ 135 ].…”
Section: Sfn In Bladder Cancermentioning
confidence: 99%
“…The antitumor effect of SFN was associated with downregulation of both the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor 2 (HER2/neu) [ 106 ]. This is remarkable, since inhibition of either EGFR or HER2 signaling has been shown to correlate with enhanced p38 MAPK phosphorylation [ 134 ]. Gemcitabine or cisplatin treatment in human bladder cancer models has been shown to cause a dose-dependent release of ROS and activate the p38 MAPK-signaling pathway [ 135 ].…”
Section: Sfn In Bladder Cancermentioning
confidence: 99%